Moderna Inc. (NASDAQ: MRNA) has announced today the results of the Phase 3 study of mRNA-1273. mRNA-1273 is the vaccine candidate of Moderna Inc. against COVID-19. The company dislcosed that its vaccine candidate has achieved 94.5% success in Phase III Study.

The study which is known as COVE has been conducted in collaboration with the Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID). Almost 30,000 volunteers have participated in the study.

The first interim analysis has assessed the 95 participants with confirmed COVID19 cases. 90 cases out of 95 were reported in the placebo group as compared to the 5 cases were in the mRNA-1273 study. The result has shown a 94.5% success in the treatment of COVID-19 patients.

A secondary endpoint assessed the 11 severe cases of COVID-19. Moderna Inc revealed that all the severe cases occurred in placebo but not a single case was reported in the mRNA-1273 vaccinated group.

To celebrate the success of its COVID-19 vaccine candidate, Moderna Inc. has revealed that it has decided to apply for Emergency Use Authorization (EUA) in the coming weeks. Earlier, Pfizer and BioNTech SE have disclosed the success of their COVID-19 vaccine candidate. Companies candidates have shown 90% effectiveness in treating the patients.

Moderna, Inc. (MRNA) has seen some recent volatility in the stock market and its shares are trading at $97.29. Traders are starting to take interest in MRNA as the shares traded as high as $103.20 and as low as $93.30 in the previous market session.

Moderna, Inc. (MRNA) average trading volume is 9.08M. However, in the previous market session Moderna, Inc. (MRNA) traded 55,233,797 shares. The 1st support level on MRNA is $94.85. MRNA 50 day moving average is $72.93 and MRNA 200 day moving average is $67.91.

Moderna, Inc. (MRNA) current performance has been shown by the recent movement in MRNA shares. MRNA has performed 18.27% over the past 30 days, MRNA has performed 28.14% over the past 90 days and MRNA has shown 387.40% over the past 1 year. Moderna, Inc. (MRNA) has a 12 month range of $17.68 to $103.20. Moderna, Inc. (MRNA) is trading 453.49% from its 12 month low and 2.78% from its 12 month high. Moderna, Inc. (MRNA) is showing a 7.09% short float showing the quantity short in the float.

MRNA has 394.68M shares outstanding and 355.80M shares in the float. Moderna, Inc. (MRNA) presently has a market cap of $34.75B and an income of -597.70M. The EPS next quarter for MRNA is -0.76 and the forecasted EPS next year is 214.00%. The market cap of Moderna, Inc. (MRNA) at $34.75B represents how many Traders own shares of MRNA and is calculated off the last price ($97.29) of MRNA and the quantity of shares outstanding (394.68M) with Moderna, Inc. (MRNA).

Moderna, Inc. (MRNA) has aggregate cash (mrq) of 3.28B, aggregate cash per share (mrq) of 8.28, aggregate debt of MRNA remains at 212.29M and aggregate debt/equity (mrq) is 7.69. . Moderna, Inc. (MRNA) operating cash flow (ttm) is 663.66M, MRNA leveraged free cash flow (ttm) is 734.49M.

MRNA is trading 33.98% above (bullish) its SMA20, 39.00% above (bullish) its SMA50 and 73.89% above (bullish) its SMA200.